MUSCLE MASS AND MUSCLE FUNCTION IN PATIENTS WITH CHRONIC KIDNEY DISEASE: COMPARATIVE ASSOCIATIONS OF SARCOPENIA INDEX, CREATININE/CYSTATIN C RATIO, AND ESTIMATED GLOMERULAR FILTRATION RATES DIFFERENCE
Main Article Content
Abstract
Objective: To compare the associations of SI, the Cre/CysC ratio, and eGFRdiff with muscle mass and muscle function in patients with chronic kidney disease.
Methods: This cross-sectional study included 90 patients with chronic kidney disease. Muscle mass was assessed using the SMI. Muscle function was evaluated by HGS and walking time as a measure of physical performance. Associations of SI, Cre/CysC, and eGFRdiff with SMI, HGS, walking time, BMI, and age were analyzed using Pearson or Spearman correlation coefficients as appropriate for data distribution.
Results: SI showed moderate to strong associations with muscle mass and function, including positive correlations with SMI (r = 0.488; p < 0.001) and HGS (r = 0.654; p < 0.001), and negative correlations with walking time (r = -0.429; p < 0.001) and age (r = -0.506; p < 0.001), while showing no association with BMI (r = 0.08; p = 0.428). The Cre/CysC ratio was also significantly associated with SMI (r = 0.377; p < 0.001), HGS (r = 0.537; p < 0.001), walking time (r = -0.317; p = 0.002), and age (r = -0.215; p = 0.042), and was not associated with BMI (r = -0.084; p = 0.432). In contrast, eGFRdiff was not associated with SMI, walking time, or BMI, and showed only a weak association with HGS (r = 0.231; p = 0.028).
Conclusion: In patients with chronic kidney disease, SI demonstrates the strongest and most consistent associations with measures of muscle function and aging, whereas the Cre/CysC ratio reflects both muscle mass and muscle function with minimal influence from BMI. In contrast, eGFRdiff shows limited associations with muscle-related parameters. These findings suggest that SI and the Cre/CysC ratio are more suitable than eGFRdiff for reflecting muscle status in patients with chronic kidney disease.
Article Details
Keywords
Chronic kidney disease, muscle mass, muscle function, sarcopenia index, creatinine/cystatin C ratio, eGFRdiff.
References
[2] Yamada S, Arase H, Shojima M, Ago T, Nakano T. Comparative validation of serum creatinine- and cystatin C-based surrogate markers for skeletal muscle mass in patients with non-dialysis chronic kidney disease. Renal Replacement Therapy, 2025, 11 (1): 63. doi: 10.1186/s41100-025-00660-5.
[3] Lin Y.L, Chen S.Y, Lai Y.H, Wang C.H, Kuo C.H, Liou H.H et al. Serum creatinine to cystatin C ratio predicts skeletal muscle mass and strength in patients with non-dialysis chronic kidney disease. Clin Nutr, 2020, 39 (8): 2435-41. doi: 10.1016/j.clnu.2019.10.027.
[4] Lin Y.L, Wang C.H, Chang I.C, Hsu B.G. A novel application of serum creatinine and cystatin C to predict sarcopenia in advanced CKD. Front Nutr, 2022, 9: 828880. doi: 10.3389/fnut.2022.828880.
[5] Shah L.N, Leonard M.B, Ziolkowski S.L, Grimm P, Long J. Cystatin C and creatinine concentrations are uninformative biomarkers of sarcopenia: a cross-sectional NHANES study. J Ren Nutr, 2023, 33 (4): 538-45. doi: 10.1053/j.jrn.2023.01.012.
[6] Yim J, Son N.H, Kim K.M, Yoon D, Cho Y, Kyong T et al. Establishment of muscle mass-based indications for the cystatin C test in renal function evaluation. Frontiers in Medicine, 2022, 9: 1021936. doi: 10.3389/fmed.2022.1021936.
[7] Tabara Y, Kohara K, Okada Y, Ohyagi Y, Igase M. Creatinine-to-cystatin C ratio as a marker of skeletal muscle mass in older adults: J-SHIPP study. Clin Nutr, 2020, 39 (6): 1857-62. doi: 10.1016/j.clnu.2019.07.027.
[8] Lee H.S, Park K.W, Kang J, Ki Y.J, Chang M, Han J.K et al. Sarcopenia index as a predictor of clinical outcomes in older patients with coronary artery disease. J Clin Med, 2020, 9 (10). doi: 10.3390/jcm9103121.
[9] An J.N, Kim J.K, Lee H.S, Kim S.G, Kim H.J, Song Y.R. Serum cystatin C to creatinine ratio is associated with sarcopenia in non-dialysis-dependent chronic kidney disease. Kidney Res Clin Pract, 2022, 41 (5): 580-90. doi: 10.23876/j.krcp.21.214.